Cited by 123Birth, Development, and HealthPregnancy and preeclampsia studiesPrenatal Substance Exposure Effects

Foetal and placental 11 β‐HSD 2: a hub for developmental programming

Cottrell, E. C., Seckl, J. R., Holmes, M. C., Wyrwoll, C. S.·2014·Acta Physiologica

Abstract

Foetal growth restriction (FGR), reflective of an adverse intrauterine environment, confers a significantly increased risk of perinatal mortality and morbidity. In addition, low birthweight associates with adult diseases including hypertension, metabolic dysfunction and behavioural disorders. A key mechanism underlying FGR is exposure of the foetus to glucocorticoids which, while critical for foetal development, in excess can reduce foetal growth and permanently alter organ structure and function, predisposing to disease in later life. Foetal glucocorticoid exposure is regulated, at least in part, by the enzyme 11 β‐hydroxysteroid dehydrogenase type 2 (11 β‐HSD 2), which catalyses the intracellular inactivation of glucocorticoids. This enzyme is highly expressed within the placenta at the maternal–foetal interface, limiting the passage of glucocorticoids to the foetus. Expression of 11 β‐HSD 2 is also high in foetal tissues, particularly within the developing central nervous system. Down‐regulation or genetic deficiency of placental 11 β‐HSD 2 is associated with significant reductions in foetal growth and birth weight, and programmed outcomes in adulthood. To unravel the direct significance of 11 β‐HSD 2 for developmental programming, placental function, neurodevelopment and adult behaviour have been extensively investigated in a mouse knockout of 11 β‐HSD 2. This review highlights the evidence obtained from this mouse model for a critical role of feto‐placental 11 β‐HSD 2 in determining the adverse programming outcomes.

Integrity signals

Registry

Crossref · 10.1111/apha.12187

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Resultant exposure to elevated levels of cortisol may contribute to developmental programming of the fetal hypothalamic-pituitary-adrenal axis and other organ systems.

    “Resultant exposure to elevated levels of cortisol may contribute to developmental programming of the fetal hypothalamic-pituitary-adrenal axis and other organ systems (127, 129, 306).”

    From Placental Origins of Chronic Disease (2016) · cites this paper as [129]

  • The same stresses may compromise the protective, barrier functions of the placenta, allowing exposure of the embryo/fetus to abnormally high levels of maternal glucocorticoids, drugs (both therapeutic and recreational), xenobiotics and pathogens.

    “Secondly, the same stresses may compromise the protective, barrier functions of the placenta, allowing exposure of the embryo/fetus to abnormally high levels of maternal glucocorticoids, drugs (both therapeutic and recreational), xenobiotics and pathogens (129).”

    From Placental Origins of Chronic Disease (2016) · cites this paper as [129]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Cottrell, E. C., Seckl, J. R., Holmes, M. C., & Wyrwoll, C. S.
Affiliations
  • University of Manchester (GB)
  • University of Edinburgh (GB)
  • The University of Western Australia (AU)
Corresponding author
Wyrwoll, C. S.
Venue
Acta Physiologica
Publisher
Wiley
Published
2013-12-12
Volume
210
Issue
2
Pages
288-295
ISSN
  • 1748-1708 (ISSN-L)
  • 1748-1716
OpenAlex
W1968311059
Cited by
123
References
61
Citations by year
2026: 4 · 2025: 10 · 2024: 9 · 2023: 6 · 2022: 10 · 2021: 25 · 2020: 8 · 2019: 13 · 2018: 12 · 2017: 11 · 2016: 9 · 2015: 5 · 2014: 1
FWCI
0.71
Type
journal article
Language
en
Open access
closed
Locations
  • Acta Physiologica (publishedVersion)
  • PubMed (publishedVersion)
  • UWA Profiles and Research Repository (UWA) (submittedVersion)
Funders
Wellcome Trust (WT079009)
Topics
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Birth, Development, and Health
  • Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Substance Exposure Effects
Keywords
11β-hydroxysteroid dehydrogenase type 2, placenta, fetal growth restriction, developmental programming, glucocorticoid exposure, low birth weight, brain development, adult behavior, perinatal mortality
MeSH terms
Animals, Female, Fetal Growth Retardation, Fetus, Glucocorticoids, Placenta, Pregnancy, Metabolic Syndrome, 11-beta-Hydroxysteroid Dehydrogenase Type 2, Fetal Development, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review